Markets
Rhythm Stock Plunges 10%, Wiping Out $655 Million, As It Commits $350 Million To LG Chem
Shares fell on the day Rhythm reported $92.13 million in quarterly revenue and agreed to a $350 million payment to cut a drug royalty.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Markets
Shares fell on the day Rhythm reported $92.13 million in quarterly revenue and agreed to a $350 million payment to cut a drug royalty.
Markets
The scanner maker raised its full-year outlook, but its gross margin fell from 48.0% a year earlier.
Markets
The payments company held its 2026 outlook and announced a $500 million buyback despite a $6.45 billion non-cash goodwill write-down.
SEC Filings
Three branded drugs grew 33% in local currency to about $1.1 billion, offsetting a 2% revenue dip from generic lenalidomide competition.
Earnings
Ferrari raised its full-year guidance, and its CFO told analysts a heavy 2026 run of special series is by design and will fade.
Markets
The Rezdiffra maker posted $55.4 million in profit on $431.3 million in drug sales, and a second cirrhosis trial is planned.
Markets
Sales rose 32% and free cash flow climbed, but shortfalls in subscription revenue and order volume drove the selloff.
Markets
SK hynix's convertible preferred holding carries director nomination rights and a standstill that limits proxy fights.
Markets
The software maker raised its sales outlook but trimmed margin and cash flow targets to absorb Arize, and announced a $1 billion buyback.
Markets
Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.
Markets
The Southeast Asian super-app also posted record adjusted EBITDA of $237 million, with its financial arm turning profitable.
Markets
Shares rebounded after a revenue beat and a $1.6 billion to $1.65 billion forecast, though free cash flow turned negative.